ACRS News and Press, Aclaris Therapeutics Inc. From 02/25/21

Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021 ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid...

Aclaris Therapeutics (ACRS) jumped 13% after a report that the company hired banks to explore a potential sale.The company allegedly has hired two investments banks to consider a potential sale, according a Street Insider report.Aclaris didn't immediately return Seeking Alpha reques...

WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present ...

WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at th...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The Dow Jones and S&P 500 indexes fell slightly on Friday but clawed back from their worst losses, while the Nasdaq edged higher to another record clos...

Aclaris Therapeutics (ACRS) has priced its public offering of ~5.5M common shares at $17.50/share, for expected gross proceeds of ~$96M.Underwriters' over-allotment is an additional ~822.6K shares.Closing date is January 22.Shares up 10% premarket.Previously: Aclaris Therapeutics re...

Aclaris Therapeutics (ACRS) plans to offer and sell shares in an underwritten public offering; underwriters granted 30-day option to purchase additional 15% of shares.Actual size, offer terms not yet disclosed.Shares -4.9% after-hours. For further details see: Aclaris Therapeutics readi...

Shares of Aclaris Therapeutics (NASDAQ: ACRS) surged on Tuesday, following the release of promising data regarding its experimental treatment for rheumatoid arthritis. As of 12:20 a.m. EST today, the pharmaceutical company's stock price was up 212%. Aclaris Therapeutics ...

Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Tenax Therapeutics (TENX)...

Tenax Therapeutics, Inc. (TENX) +70% after announcing acquisition of PH Precision Med.Aclaris Therapeutics (ACRS) +66% on positive data from mid-stage rheumatoid arthritis.Minerva Neurosciences (NERV) +42% on announcing sale of Seltorexant Royalty for up to $155M.China Natural ...